The need for intranasal drug and vaccine delivery has significantly increased owing to the increasing patient preference for nasal drug delivery as a result of easy administration and better efficacy. The delivery of drugs via nasal route is considered as one of the most favoured drug delivery methods by patients as well as by healthcare providers. This is due to the non-invasive nature of the delivery of the drug and better drug absorption via the nasal route. Furthermore, compared to the other routes, the nasal path offers a less aggressive environment and this allows better drug absorption. Hence, this is likely to flourish the demand for intranasal drug and vaccine delivery during the forecast period.          

In addition, due to the growing patient compliance, this has led to growing technical developments related to nasal drug delivery systems. For example, there is increasing clinical support for the treatment of central nervous system disorders by administrating drugs through the nasal route. Also, at higher concentrations, the nasal route will cross the blood-brain barrier. This offers better options for treating patients suffering from CNS conditions without needles. However, moderate complications and side effects associated with the use of nasal products can impede the growth of the global market.

Furthermore, as different nasal drug delivery technologies for the administration of COVID-19 vaccines are under development by market players, the market is expected to gain traction over the forecast period. For example, Bharat Biotech initiated clinical trials for the COVID-19 nasal drop vaccine on 7 April 2020. The group has partnered with vaccine manufacturer FluGen and the University of Wisconsin-Madison to conduct clinical trials in the United States.       Thus, this will further boost the intranasal drug and vaccine delivery market.

The global intranasal drug and vaccine delivery market has been segmented based on product type, dosage, application, distribution channel and region. Based on product type, the intranasal drug and vaccine delivery market is segmented into powder delivery device, liquid delivery device, pressurized metered dose inhaler and others wherein the liquid delivery device segment dominated the market. Various formulations, such as aqueous solutions, emulsions, and suspensions, are available. It is anticipated that regular developments and the launch of novel devices for different indications would boost segment growth. In March 2019, for example, Aptar Pharma, a supplier of drug delivery systems, earned the U.S. FDA approval for the nasal spray system Bidose.

On the basis of dosage, the intranasal drug and vaccine delivery market is segmented into unit-dose, and multi-dose. The Multi-dose spray pumps segment dominated the market as they provide patients suffering from chronic diseases, such as allergic rhinitis, with a cost-effective, easy and safe alternative.

Based on application, the intranasal drug and vaccine delivery market is segmented into respiratory disorders, neurological disorder, vaccination, pain management, and others. The respiratory disorders segment dominated the market in 2019 due to the use of intranasal devices such as asthma, nasal inflammation, and allergic rhinitis to treat a number of respiratory disorders.

Based on distribution channel, the intranasal drug and vaccine delivery market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The retail segment dominated the market due to the growing awareness of patients, self-administration, and increasing concentration on positive medical results. In addition, software developers work in partnership with different pharmacy chains to make various point-of- care drugs available without prescription.

The global intranasal drug and vaccine delivery market is cumulative to North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America dominated the global intranasal drug and vaccine delivery market in 2019, however Asia Pacific is expected to grow at a highest pace through 2028.

North America, especially the U.S. dominates the global intranasal drug and vaccine delivery market. This is due to the increasing prevalence of asthma and chronic obstructive pulmonary disease and the increasing acceptance of early treatment procedures. As well as it is attributed to advanced technology, product launches and creativity. As the third leading cause of death in the United States is found to be chronic obstructive pulmonary disease, the rising prevalence of COPD can therefore help to increase the adoption of intranasal drug and vaccine delivery devices.

Asia Pacific is expected to be the fastest growing regional market for intranasal drug and vaccine delivery owing to factors such as the existence of a large patient base, growing medical tourism, rising healthcare spending by the government, and acceptance of non-invasive treatments. In addition, it is also due to the availability of efficient care options, high clinical needs that are not met, growing levels of disposable income and increasing awareness of these items.